Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, si
Authors
Philip G. Ferstl (ORCID: https://orcid.org/0000-0002-0836-6643)
Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, si
Philip G. Ferstl, Fabian Finkelmeier, Meriam Kabbaj, Johannes Masseli et al.
Journal
The Lancet. Gastroenterology & hepatology
Topics
Liver Disease and Transplantation
article
Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, si
Philip G. Ferstl, Fabian Finkelmeier, Meriam Kabbaj, Johannes Masseli, Sophie Biguenet, Katharina Staufer, Olaf Tyc, Wenyi Gu, Martin Sebastian McCoy, Kai-Henrik Peiffer, Maximilian Joseph Brol, Frank Erhard Uschner, Stefan Zeuzem, Jonel Trebicka